• Siegfried acquires majority stake in DiNAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies

    Ad Hoc

    Siegfried announces the acquisition of a 95% stake in DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and gene therapies

  • Siegfried begins construction of a new global R&D Center for Drug Substances in Evionnaz

    Media Release

    Siegfried broke ground to build a new global R&D Center for Drug Substances at its site in Evionnaz, Switzerland

  • Siegfried increases distribution and appoints new board member

    Media Release

    Siegfried Holding AG’s shareholders approved all proposals of the Board of Directors. They approved the increase in the distribution to shareholders in the form of repayment from share capital from 3.20 to 3.40 Swiss francs per registered share.

  • Siegfried opens global Development Center for Drug Products in Barcelona

    Media Release

    Siegfried inaugurates a state-of-the-art Development Center for Drug Products in Barcelona, including dedicated facilities for highly potent Drug Products

  • On the move since 150 years: Siegfried significantly increases sales and profits in 2022

    Ad Hoc

    Net sales up to CHF 1.229 billion (+15.6% increase versus prior year in local currencies). Core EBITDA of CHF 272.5 million (prior year CHF 207.2 million) at an expanded margin of 22.2% (prior year 18.8%)

  • Siegfried appoints Christian Dowdeswell as Chief Business Officer Drug Substances

    Media Release

    Christian Dowdeswell will become Chief Business Officer Drug Substances and member of Siegfried’s Executive Committee. Marianne Späne will continue to lead the business development and sales activities in the area of finished dosage forms as Chief Business Officer Drug Products.